Obtain pharmacology data that translate to clinical response with the only in vitro drug screening services using patient-derived cell (PDC) models.
predictTx Screen leverages the power of high-content imaging to provide key information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process.
Cost efficient screening service compared to stand-alone studies
Simple model selection from a panel of 50 well-characterised PDCs across 18 different solid tumour types
Model characterisation data including NGS, patient treatment history, in vitro drug response to standard of care
Proven predictive power over patient response in the clinic
89% positive predictive value
99% negative predictive value
Fast data turnaround
Scalable patient-derived models for dose escalation and repeat studies
Amenable to small molecule and biotherapeutics screening
Find relevant therapies
Fresh tumour sample collected from patient, brought to our lab and developed into a PDC.
Around 60 drugs dosed on sample. Effects analysed using high-content screening. Results highlight suitable treatments and reported to oncologist.
PDC expanded and cryogenically preserved in Imagen biobank.
Rapid discovery and development of new therapies
Agree objectives and select from 100’s of PDC models in our database (fully characterised, including WES/RNAseq).
Re-derive and grow PDC models, dose according to protocol.
Analyse data and generate endpoints (IC50’s, amongst others).
2D assay format
Cell death and cell count read-out
Standard 3 days treatment, extendable to 7 days
8-point dose response curve/drug
10 models minimum from a 50 model panel
